Vertex Pharmaceuticals Q4 FY25: where the revenue came from and where it went
The whole income statement of Vertex Pharmaceuticals for this quarter, as one diagram: what earned the revenue, and what it went on.
- Period
- Oct 1 – Dec 31, 2025
- Reported
- Feb 13, 2026
Revenue$3.19B
+10% year over year
Gross profit$2.72B
85% margin
Operating profit$1.21B
38% margin
Net profit$1.19B
37% margin
The numbers
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 3.19 | 100% | +10% |
| Trikafta/Kaftrio | 2.57 | 81% | −5% |
| Alyftrek | 0.38 | 12% | |
| Manufactured product other | 0.24 | 7% | +24% |
| Cost of revenue | −0.47 | 15% | |
| Gross profit | 2.72 | 85% margin | +0pp |
| SG&A | −0.49 | 15% | +2pp |
| Other | −1.03 | 33% | +0pp |
| Operating profit | 1.21 | 38% margin | +3pp |
| Other income, net | 0.13 | ||
| Tax | −0.14 | ||
| Net profit | 1.19 | 37% margin | +6pp |
175 of 418 companies, most recently reported first
New results in your inbox
When a big company reports, we send you a link to its diagram before anyone has time to comment on it. This is a mailing list, not an account: it does not open the diagrams by itself. No spam, one-click unsubscribe.
Drag or use the arrow keys to see the rest